Aaron Block, MBA

Senior Director Business Development at Ariceum Therapeutics

Aaron Block, MBA has a diverse work experience spanning various roles and industries. In 2007, they started their career as a Medical Laboratory Technician at Newton-Wellesley Hospital. Aaron then worked as an Undergraduate Researcher at Pennsylvania State University - Dr. Victoria Braithwaite's Lab from 2009 to 2010. In 2010, they joined Tufts University - Dr. Jun Xu's Lab as a Research Technician. In 2012, Aaron became a Professional Research Assistant at the University of Colorado Denver - Dr. Huntington Potter's Lab, where they worked until 2016.

In 2017, Aaron held multiple roles at different companies. Aaron served as a Consultant at Daegu Digital Promotion Agency and as a Research Analyst at MassBio. At Leuko, they worked as a Business Analyst. From 2018 to 2022, they were the Director of Project Management and Business Development at Theragnostics. From 2022 to 2023, they held the position of Senior Director of Project Management and Business Development at the same company.

Currently, Aaron is working as the Senior Director of Business Development at Ariceum Therapeutics, starting in 2023. Throughout their career, Aaron has showcased their expertise in project management, business development, and research.

Aaron Block, MBA, holds a Master of Business Administration (M.B.A.) degree in Health Sector Management from the Questrom School of Business at Boston University (2016-2018). Prior to that, they obtained their Bachelor of Science (B.S.) degree in Biology from The Pennsylvania State University - Eberly College of Science (2006-2010). During their undergraduate years, Aaron Block also earned a Minor in Psychology from The Pennsylvania State University (2006-2010). Additionally, they obtained a certification as a Six Sigma Green Belt from the Boston University Questrom School of Business and The Council for Six Sigma Certification in May 2017.

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Ariceum Therapeutics

1 followers

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.


Headquarters

Berlin, Germany

Employees

11-50

Links